Gangliosides and Antigangliosides in Malignant Melanoma

Ene, Corina-Daniela; Nicolae, Ilinca

doi:10.5772/59176

Cited by 5 publications

(3 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study showed no significant increase in quantitative determination of TuM2-PK in patients with T1N0Mo ccRCC compared with healthy subjects. The plasmatic level of TuM2-PK in patients with ccRCC was correlated with IL-8 levels, data that suggest a possible interaction between these markers and tumoral neoangiogensis [101][102][103][104][105][106]. A recent report showed that the extracellular level of TuM2-PK in patients with localized renal cell carcinoma was 3.2-fold lower compared with patients with disseminated disease [107].…”

Section: Discussionmentioning

confidence: 95%

Posttranslational Modifications Pattern in Clear Cell Renal Cell Carcinoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

Posttranslational modifications are dynamic enzymatic-mediated processes, regulated in time and space, associated with cancer development. We aimed to evaluate the significance of posttranslational modifications in the pathogenesis of clear cell renal cell carcinoma. The authors developed a prospective, observational study during a period of three years and included 55 patients with localized renal cell carcinoma and 30 heathy subjects. Glycosylation, nitration and carbonylation, thiol-disulfide homeostasis, methylation, phosphorylation and proteolytic cleavage were evaluated in the serum of the evaluated subjects in the present study. Our results showed some characteristics for early ccRCC: high production of cytokines, substrate hypersialylation, induced nitrosative and carbonylic stress, arginine hypermethylation, thiol/disulfide homeostasis (TDH) alteration, the regulatory role of soluble receptors (sRAGE—soluble receptor for advanced glycation end products, sIL-6R—soluble receptor for Interleukin 6) in RAGE and IL-6 signaling, the modulatory effect of TK1—thymidine kinase 1 and TuM2-PK—tumoral pyruvate-kinase 2 in controlling the level of phosphometabolites in neoplastic cells. These data could be the initial point for development of a panel of biomarkers such as total sialic acid, orosomucoids, nitrotyrosine, carbonylic metabolites, Asymmetric Dimethylarginines (ADMA), Symmetric Dimethylarginines (SDMA), and thiol-disulfide equilibrium for early diagnosis of ccRCC. Moreover, they could be considered a specific disease posttranslational modification signature which underlines the transition from early to advanced stages in this neoplasia, and of a therapeutic target in kidney oncogenesis.

show abstract

Section: Discussionmentioning

confidence: 95%

Posttranslational Modifications Pattern in Clear Cell Renal Cell Carcinoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…They can act as receptors and various biological substances, contributing to the expression of immune cell functions. Accordingly, the possibility of their application for treating prostate cancer, 23 melanoma, 24 and diabetic nephropathy 25 has been suggested, and related research is being actively conducted. According to Nicolae et al., titers of anti-GDA1a and antiGQ1b (ganglioside antibodies) were higher in patients with BPH than in controls.…”

Section: Discussionmentioning

confidence: 99%

Cervi Parvum Cornu complex for men with lower urinary tract symptoms: a multicenter, randomized, double-blind, placebo-controlled trial

Shin,

Yoon,

Kim

et al. 2023

Prostate International

View full text Add to dashboard Cite

“…It is also interesting to note that a strong association between increased serum levels of gangliosides and high Breslow index or high Clark level as well as the presence of ulceration has been reported in melanoma patients, suggesting that circulating gangliosides may serve as potential markers for melanoma staging [ 212 ].…”

Section: Discussionmentioning

confidence: 99%

New Insights into the Role of Sphingolipid Metabolism in Melanoma

Carrié

Virazels

Dufau

et al. 2020

Cells

View full text Add to dashboard Cite

Cutaneous melanoma is a deadly skin cancer whose aggressiveness is directly linked to its metastatic potency. Despite remarkable breakthroughs in term of treatments with the emergence of targeted therapy and immunotherapy, the prognosis for metastatic patients remains uncertain mainly because of resistances. Better understanding the mechanisms responsible for melanoma progression is therefore essential to uncover new therapeutic targets. Interestingly, the sphingolipid metabolism is dysregulated in melanoma and is associated with melanoma progression and resistance to treatment. This review summarises the impact of the sphingolipid metabolism on melanoma from the initiation to metastatic dissemination with emphasis on melanoma plasticity, immune responses and resistance to treatments.

show abstract

Gangliosides and Antigangliosides in Malignant Melanoma

Cited by 5 publications

References 106 publications

Posttranslational Modifications Pattern in Clear Cell Renal Cell Carcinoma

Posttranslational Modifications Pattern in Clear Cell Renal Cell Carcinoma

Cervi Parvum Cornu complex for men with lower urinary tract symptoms: a multicenter, randomized, double-blind, placebo-controlled trial

New Insights into the Role of Sphingolipid Metabolism in Melanoma

Contact Info

Product

Resources

About